Summary:
To evaluate the efficacy of repeat dose of ALD403 administered intravanously (IV) compared to placebo in patients with chronic migraine.
Qualified Participants Must:
• Be between 18 and 65 years of age
•
Have taken or was recommended a treatment for migraines by a physician
•
Have at least 15 headaches a month with at least 8 turning into a migraine
Qualified Participants May Receive:
- Compensation for time and travel expenses
- Physicals by a board certified physician
- Lab work
- Investigational medication administered on site